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Summary
Background With expanded access to antiretroviral therapy (ART) in sub-Saharan Africa, HIV mortality has decreased, 
yet life-years are still lost to AIDS. Strengthening of treatment programmes is a priority. We examined the state of an HIV 
care programme in Kenya and assessed interventions to improve the impact of ART programmes on population health.
Methods We created an individual-based mathematical model to describe the HIV epidemic and the experiences of 
care among adults infected with HIV in Kenya. We calibrated the model to a longitudinal dataset from the Academic 
Model Providing Access To Healthcare (known as AMPATH) programme describing the routes into care, losses from 
care, and clinical outcomes. We simulated the cost and eﬀ ect of interventions at diﬀ erent stages of HIV care, including 
improvements to diagnosis, linkage to care, retention and adherence of ART, immediate ART eligibility, and a universal 
test-and-treat strategy.
Findings We estimate that, of people dying from AIDS between 2010 and 2030, most will have initiated treatment (61%), 
but many will never have been diagnosed (25%) or will have been diagnosed but never started ART (14%). Many 
interventions targeting a single stage of the health-care cascade were likely to be cost-eﬀ ective, but any individual 
intervention averted only a small percentage of deaths because the eﬀ ect is attenuated by other weaknesses in care. 
However, a combination of ﬁ ve interventions (including improved linkage, point-of-care CD4 testing, voluntary 
counselling and testing with point-of-care CD4, and outreach to improve retention in pre-ART care and on-ART) would 
have a much larger impact, averting 1·10 million disability-adjusted life-years (DALYs) and 25% of expected new 
infections and would probably be cost-eﬀ ective (US$571 per DALY averted). This strategy would improve health more 
eﬃ  ciently than a universal test-and-treat intervention if there were no accompanying improvements to care ($1760 per 
DALY averted). 
Interpretation When resources are limited, combinations of interventions to improve care should be prioritised over 
high-cost strategies such as universal test-and-treat strategy, especially if this is not accompanied by improvements to 
the care cascade. International guidance on ART should reﬂ ect alternative routes to programme strengthening and 
encourage country programmes to evaluate the costs and population-health impact in addition to the clinical beneﬁ ts 
of immediate initiation.
Funding Bill & Melinda Gates Foundation, United States Agency for International Development, National Institutes 
of Health.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The provision of antiretroviral therapy (ART) has 
substantially reduced HIV mortality.1 With timely 
diagnosis, treatment initiation, and good adherence, 
life-expectancy for people with HIV can approach that of 
uninfected people.2 However, life-years are still lost 
to AIDS, and in sub-Saharan Africa, hundreds of 
thousands of AIDS-related deaths occur each year.3
Reasons for continued health losses to HIV when ART 
is widely available are poorly understood. The care 
cascade describes the series of engagements with the 
health system through which people with HIV must pass 
to beneﬁ t fully from ART, beginning with HIV testing, 
and ending with regular monitoring of patients in a state 
of sustained viral suppression. In 2011, Rosen and Fox4 
showed that fewer patients reach each successive stage of 
HIV care in sub-Saharan Africa, and representations of 
the care cascade in diﬀ erent settings followed.5 However, 
many attempts to quantify the care cascade have been 
limited by not being able to follow a cohort of patients 
through all stages of care. Data are typically available only 
for people with HIV who present to clinics and therefore 
exclude those who never engage in care and who are 
likely to have the greatest health losses.6,7 Diﬀ erences in 
care-seeking behaviour between patients who actively 
seek care (through clinics) and those who are actively 
sought (through outreach programmes) lead to 
fundamental uncertainties in the operation of the care 
cascade, in particular, the extent to which health-care-
seeking behaviour enables patients to present for care 
and initiate treatment on becoming ill, bypassing the 
typical stages of pre-ART care, and monitoring until 
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reaching ART eligibility (in a process that we have termed 
previously as reaching ART via the side-door).6
Many strategies to improve the care cascade have been 
proposed and tested.8–10 These variously aim to improve 
testing, linkage to care, retention in care before starting 
treatment, retention on ART, and rates of viral suppression. 
However, evidence about the eﬀ ectiveness of individual 
interventions is only partly informative about the best 
strategy to improve HIV care, and most studies have not 
been able to measure the eventual population-health 
beneﬁ ts resulting from improved provision of care.
The expansion of ART eligibility to potentially all people 
with HIV as recommended in the latest WHO guidelines 
(ie, immediate ART initiation)11 and increased outreach 
to populations for testing (eg, through a universal 
test-and-treat strategy) are proposals for transformational 
expansions to treatment.12,13 In hypothetical idealised 
programmes, the persuasive argument in favour of such 
approaches is that the additional initial costs would later 
become oﬀ set by savings resulting from reductions 
in HIV transmission and need for ART.12 However, 
whether these savings will be realised with more realistic 
implementation assumptions is questionable.14
Deﬁ nitions for optimal strategies to improve HIV care 
most eﬃ  ciently in health systems require insight into 
the sources of HIV mortality and morbidity for patients 
at each stage of care and a comparison of the population-
level health impact of a range of candidate interventions 
that act at diﬀ erent stages of care. We created a 
mathematical model of the HIV epidemic and care 
cascade in Kenya. The model is parameterised with data 
from an HIV care programme in western Kenya 
supported by the Academic Model Providing Access To 
Healthcare (AMPATH) collaboration, which uniquely 
includes data about people before testing and 
disengagement from care, through an integrated 
household-based testing intervention. We used the 
model to quantify the previous care experience of those 
dying from HIV in a setting with a mature (>8 years 
since established) ART programme, and to simulate the 
cost and eﬀ ect of HIV care interventions, in isolation 
and in combinations. From this information, we aimed 
to generate recommendations about optimal strategies 
for HIV care programmes to maximise health costs 
eﬀ ectively.
Methods
Data sources
We constructed an individual-based microsimulation 
model representing the HIV epidemic in Kenya and 
capturing the care experience of individuals as they 
progress through an ART programme.
 Research in context 
Evidence before this study 
With global aspirations to eliminate AIDS as a cause of 
population morbidity and death, attention has turned to 
identiﬁ cation and reduction of weaknesses in HIV care 
programmes. As the breadth of interventions targeting aspects 
of the cascade of care expands, care programmes must identify 
which strategies will bring about the largest impact for the 
lowest cost. Mathematical models are well placed to answer 
these questions. We searched PubMed for HIV modelling 
studies published between Jan 1, 2000, and Aug 2, 2016, with 
the terms “HIV” AND (“ART” OR “antiretroviral therapy”) AND 
(“cascade” OR “continuum”) AND (“modelling” OR “modeling” 
OR “model”) without any language restrictions. The search 
yielded 65 abstracts and 12 met our inclusion criteria of being 
mathematical modelling studies. Previous studies have relied 
on aggregated routine data from disparate analyses and 
populations to estimate the cascade, and consequently most 
have used deterministic compartmental models to do 
investigations on individual interventions. Only four studies 
have assessed the cost-eﬀ ectiveness of interventions targeting 
improvements in care. Among these, analysis of the eﬀ ect of 
early ART initiation in a study in India showed such an 
intervention would be highly cost-eﬀ ective, but the researchers 
stressed the importance of the modulatory eﬀ ects of retention 
in care. Findings from analyses of the cascade in the USA 
corroborate these results. The only study from our search to use 
an individual-based model described HIV transmission and 
cascade progression in South Africa. Results indicated that 
among the interventions implemented, returning and 
reinitiating patients onto ART is highly cost-eﬀ ective along 
with improving retention in care.
Added value of this study 
Our model shows that single interventions have a modest eﬀ ect 
on improving present care programmes. A combination of 
interventions concurrently strengthening various aspects of 
care is the most cost-eﬀ ective strategy to improve outcomes for 
patients. This strategy is likely to be more cost-eﬀ ective and 
generate greater impacts than immediate ART that is not 
accompanied by improvements to the care cascade. Our model 
represents HIV care and treatment in western Kenya, but our 
overall conclusions will have the same broad relevance to the 
many other settings with large generalised epidemics and 
established ART programmes.
Implications of all the available evidence 
Many health systems do not capture a large proportion of 
HIV-related deaths occurring outside of the clinic. There is 
considerable scope for care programmes to improve care 
throughout the cascade. Detailed longitudinal data about ART 
health-care programmes could improve future projections, 
characterise country-speciﬁ c gaps in care, and identify 
cost-eﬀ ective strategies to achieve future treatment targets.
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The model represents births, ageing, deaths, and HIV 
transmission in the Kenyan population (appendix 
pp 5–8). After infection, disease progression is modelled 
by an individual progressing to a lower CD4 count 
category (>500 cells per μL, 350–500 cells per μL, 
200–350 cells per μL, and <200 cells per μL) and of 
greater disease severity (WHO deﬁ ned stages 1, 2, 3, 
and 4; appendix p 12). Both CD4 cell count and disease 
state aﬀ ect the risk of mortality. Additionally, WHO 
disease stage aﬀ ects the propensity to seek care (appendix 
pp 12–18). When treatment is initiated, patients can 
transition to a higher CD4 cell count and a lower 
(healthier) WHO clinical stage (appendix p 12).
Model design
The model describes the pathway through care for each 
individual infected with HIV (ﬁ gure 1, appendix p 19). The 
baseline scenario represents no additional intervention.
The HIV care and treatment components of the model 
were parameterised with observed patients’ data from 
Bunyala, western Kenya (appendix pp 19–44). HIV 
testing, HIV care, and treatment services were 
established in 2006 in district hospital and health centres, 
supported by the AMPATH collaboration. AMPATH is a 
partnership established in 2001 between Moi Teaching 
and Referral Hospital, Moi University School of 
Medicine, and a consortium of universities from North 
America in response to the HIV epidemic in Kenya 
(appendix pp 19–20). All patients’ visits from 2004 have 
been recorded electronically in the AMPATH Medical 
Record System, furnishing information about retention 
and outcomes. For patients to seek care in non-AMPATH 
clinics they must leave the AMPATH catchment area 
(appendix pp 19–20). Patients lost from care are traced 
and actively followed up to ascertain their outcome, 
either through direct contact or discussions with family 
members if patients cannot be found. In the area of 
Bunyala, there have been two rounds of home-based 
counselling and testing campaigns since 2010, the ﬁ rst 
of which achieved more than 85% coverage of the 
community.15 These early rounds of home-based 
counselling and testing involved passive referral of 
patients infected with HIV, with no active follow-up to 
Figure 1: Operational steps involved in navigating an ART programme
Blue arrows show linkage step in which patients were seen by a clinician and had blood taken for a CD4 test. Grey arrows show the shortcut to immediate ART 
initiation taken by individuals presenting with WHO stage 3 or 4 symptoms. Dashed arrow shows ART reinitiation after loss from ART care (does not occur in the 
baseline programme). ART=antiretroviral therapy.
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AMPATH data Model
2007–10 2010–11 2011–14 2007–10 2010–11 2011–14
People diagnosed with HIV who entered care by route into care
HBCT ·· 7% 60% ·· 13% 64%
VCT 66% 47% 20% 65% 48% 20%
PICT 34% 46% 20% 35% 39% 16%
Proportion of individuals in CD4 strata at ART initiation
>500 cells per μL 9% 14% 19% 10% 12% 9%
350–500 cells per μL 7% 8% 18% 11% 12% 9%
200–350 cells per μL 18% 21% 41% 14% 12% 46%
<200 cells per μL 66% 57% 22% 65% 64% 36%
AMPATH data were analysed in three discrete time periods: 2007–10 marking the period of time before household-based 
testing where individuals could only seek care through VCT or PICT, 2010–11 in which HBCT was rolled out in Bunyala 
(Kenya), and 2011–14 when HBCT was fully implemented and treatment eligibility guidelines had been updated to less 
than 350 cells per μL or WHO stage 3–4. See appendix pp 25–28 for corresponding ﬁ gures. AMPATH=Academic Model 
Providing Access To Healthcare. HBCT=home-based counselling and testing. VCT=voluntary counselling and testing. 
PICT=provider-initiated counselling and testing. ART=antiretroviral therapy.
 Table 1: Summary of agreement between AMPATH data and the model
See Online for appendix
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facilitate linkage to health care (appendix p 24). Present 
AMPATH home-based counselling and testing cam-
paigns now include active follow-up, and we expect 
linkage rates to be substantially higher.
We characterised the main parameters of the care 
cascade through the analysis of the linked individual 
clinical and home-based counselling and testing records 
after extensive removal of incorrectly entered data and 
removal of duplication (appendix p 21).15 For model 
parameters that did not correspond to quantities that can 
be directly observed, values were inferred through ﬁ tting 
the model output to observed data (table 1, appendix pp 22, 
23, 25–28). 62% of people in both AMPATH and model 
data were diagnosed in mid-2010: 41% through voluntary 
testing and counselling in AMPATH and 42% in the 
model; 21% provide initiated counselling and testing in 
each. Of those diagnosed, AMPATH data showed 34% 
were on ART in 2010 and the model estimated 33%; by 
2014 an estimated 91% (AMPATH) and 82% (model) of 
diagnosed people were on ART.
Calibration yielded several sets of parameters for the 
model of the care cascade, which are variously in better 
agreement with diﬀ erent indicators (appendix pp 25–44).
The ART programme costs at baseline were estimated 
from the perspective of a health-care provider. Unit cost 
estimates were based on the CHAI MATCH study17 of 
ART facilities, and comprised the cost of ART care, the 
cost of pre-ART clinic visits, and the cost of CD4 laboratory-
based tests (appendix pp 45, 46). Sensitivity analysis was 
done with consideration to the variations in the unit cost 
of ART programme components (appendix pp 53–55).
Analysis of the care cascade
Interventions on the care cascade can be divided into 
those that aim to increase testing, linkage, and retention 
in pre-ART health care, or retention and suppression for 
patients on ART. We reviewed the medical literature to 
identify realistic and empirically based assumptions for 
the eﬃ  cacy and cost of representative interventions in 
each of these categories (table 2, appendix p 48).
To assess the impact of individual interventions, each 
was simulated for the duration 2010–30, and the eﬀ ect 
on patients’ outcomes compared with the baseline 
scenario in the absence of any interventions. The eﬀ ect 
of the programme was quantiﬁ ed as disability-adjusted 
life-years (DALYs) averted (appendix p 47), additional 
cost of care (appendix pp 45, 46), and HIV-related deaths 
averted, compared with a baseline programme without 
any intervention (taken to be similar in structure to 
AMPATH before the launch of household-based testing). 
Because of the stochastic nature of the model, we present 
results as the mean of ten repeat simulations.
Assumptions Cost (2013 US$)
HBCT (passive 
referral)
Every 4 years, 90% testing coverage; 30% linked to care 
immediately if not previously diagnosed; 40% if previously 
diagnosed
$18·00 per HBCT person tested ($8·00 home visit9* and $10·00 rapid 
HIV test16)
Enhanced 
counselling and 
testing
The rate of HIV testing is 125% that of baseline $50·00 per person tested ($28·00 clinic visit,17 $10·00 rapid HIV test,16 
and $12·00 CD4 laboratory test17) 
HBCT (with 
point-of-care CD4)
Every 4 years, 90% testing coverage of population; 65% linked 
to care if not previously diagnosed, 70% if previously diagnosed 
(point-of-care CD4 reduces non-linkage by 50%)
$60·00 per HBCT person tested ($8·00 home-visit,9* $10·00 rapid 
HIV-test,16 and $42·00 point-of-care CD4 test18)
Facilitated linkage The risk of failure-to-link is reduced by 50% $2·61 per diagnosed but not linked patient per year19 
VCT point-of-care 
CD4
At VCT, a point-of-care CD4 test is given to patients reducing 
the risk of not linking to 0%
$80·00 per point-of-care CD4 test ($28·00 clinic visit,17 $10·00 rapid 
HIV test,16 and $42·00 point-of-care CD4 test18
Pre-ART outreach In the middle of each year, 20% of tested individuals lost from 
pre-ART care are sought and returned
$19·55 per patient sought20
 
Improved care The risk of a patient missing an appointment is reduced by 50% $7·05 per patient per clinic visit21,22
Point-of-care CD4 A point-of-care CD4 test removes the 10% disengagement 
from care between CD4 test and receiving result
$70·00 per point-of-care CD4 test ($28·00 clinic visit17 and $42·00 
point-of-care CD4 test18)
On-ART outreach In the middle of each year, 40% of patients who had initiated 
ART and were lost from care are sought and returned
$19·55 per patient sought.20
Adherence At ART initiation, adherence to ART increases by 50% $33·54 per person on ART per year23
Immediate ART No pre-ART care, all individuals who enter care are initiated 
onto ART immediately
Only additional costs due to increased usage of ART (appendix p 45)
Universal test and 
treat
Immediate ART and HBCT (every 4 years, 90% testing coverage. 
30% linked if not previously diagnosed, 40% if previously 
diagnosed)
$18·00 per HBCT person tested ($8·00 home visit9* and $10·00 rapid 
HIV-test16)
When HBCT is applied in isolation in the model this incorporates only a passive referral of patients. Universal test and treat is a combination of HBCT and immediate ART. 
All interventions except immediate ART and universal test and treat, were considered when identifying the optimal combination of interventions acting on the cascade by 
selecting interventions with the lowest cost per disability-adjusted life-year averted. HBCT=home-based counselling and testing. VCT=voluntary counselling and testing. 
ART=antiretroviral therapy. *Secondary analysis of data from van Rooyen and colleagues;9 see appendix p 48 for further details. 
Table 2: Summary of individual interventions designed to target various aspects of care
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An optimal combination of individual cascade 
interventions (excluding universal test and treat, which 
is a composite of home-based counselling and testing 
and immediate ART) was identiﬁ ed by simulation of all 
possible combinations and selection of those that 
provided the greatest increase in health for a range of 
budget levels. We imposed the additional constraint 
that once an intervention had been included in the 
combination at one budget level, it cannot be removed 
at higher budget levels.
To assess the cost-eﬀ ectiveness of interventions, the 
cost per DALY averted was compared with the gross 
domestic product (GDP) per capita for Kenya in 2013 
(US$1242).24 We assume that an intervention is likely to 
be cost-eﬀ ective if the cost per DALY is less than 50% 
GDP per capita.25,26 Costs and DALYs were both 
discounted at 6% per annum from 2010.
Role of the funding source
The funders had no role in model construction, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author worked with co-
authors to analyse the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We projected the baseline model in the absence of any 
interventions between 2010 and 2030 and analysed the 
status of care of those dying from HIV-related causes in 
two timeframes: 2010–2015 and 2025–2030. Between 
2010 and 2030, most people will have initiated 
treatment (61%), but many will never have been 
diagnosed (25%) or will have been diagnosed but never 
started ART (14%). Among all AIDS-related deaths 
between 2010 and 2015, most occurred in individuals 
who had initiated treatment (ﬁ gure 2). Among these, 
most died because they had initiated treatment late (CD4 
count <200 cells per μL). The largest proportion of deaths 
was in people who were never diagnosed, with the 
remainder those who were diagnosed but did not initiate 
ART. By contrast, between 2025 and 2030, the distribution 
of mortality shifted to the latter stages of care. Most 
deaths still occurred in individuals who had initiated 
treatment, with the largest single proportion being in 
patients who had disengaged from ART care.
We applied each of the 12 interventions in isolation and 
calculated the DALYs averted and additional costs 
between 2010 and 2030 compared with the baseline 
scenario (ﬁ gure 3 and table 3). Costs and eﬀ ect are 
generally closely related, with low-cost interventions 
having a low impact. The eﬀ ects of most single 
interventions aﬀ ecting engagement in pre-ART health 
care cluster together with relatively low impact and low 
cost (ﬁ gure 3).
One exception is home-based counselling and testing 
(with passive referral), which has a high cost per DALY 
averted (ﬁ gure 3). We assumed that only 30% of people 
diagnosed for the ﬁ rst time at home-based counselling 
and testing will link to care without further intervention. 
This assumption is based on observations in the earliest 
home-based counselling and testing campaign at 
AMPATH, which used passive referral to care.15 
AMPATH’s present home-based counselling and testing 
programme incorporates active referral and, based on 
preliminary data, yields considerably higher linkage 
rates (a scenario with 90% linkage, consistent with 
WHO targets, is included for comparison in the 
Figure 2: Distribution of care experience of patients who died from HIV
ART=antiretroviral therapy. Late initiation is deﬁ ned as a person with a CD4 count of less than 200 cells per μL. 
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interventions acting on the cascade between 2010 and 2030
Optimal combination of interventions includes facilitated linkage, on-ART outreach, VCT point-of-care CD4, 
pre-ART outreach, and point-of-care CD4. ART=antiretroviral therapy. HBCT=home-based counselling and testing. 
VCT=voluntary counselling and testing.
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appendix p 56). Home-based counselling and testing 
(with point-of-care CD4) averts more DALYs than any 
other single intervention because of the reduced time to 
conﬁ rm eligibility and increased probability of linkage. 
However, the cost per DALY averted of $1617 is 
130% GDP per capita of Kenya (table 3).
By contrast, the on-ART outreach intervention, which 
seeks and returns 40% of people disengaged from health 
care after ART initiation, has the third lowest cost per 
DALY averted, and a larger impact than almost all 
interventions (table 3). These data are consistent with the 
large proportion of deaths and high mortality in people 
disengaged from care (ﬁ gure 2).
The two interventions that represent large changes to 
ART eligibility, immediate ART and universal test and 
treat, diﬀ er substantially in their impact and cost. 
Immediate ART provides treatment to those who present 
for care, and is eﬀ ective because it eliminates the 
potential for patients to be lost from care before they are 
conﬁ rmed to be eligible for ART. The cost per DALY 
averted is $895 (72% GDP per capita), which is not 
considered to be cost-eﬀ ective at the threshold of 
50% GDP per capita (which is becoming widely used), 
but would be considered cost-eﬀ ective with previous 
thresholds.27
The universal test-and-treat intervention has a much 
larger impact than any other intervention because the 
home-based testing results in a higher population ART 
coverage, but is much more costly because of high HIV 
testing costs. This approach is also not cost-eﬀ ective 
($1760 per DALY averted; 142% GDP per capita).
Most of the projected beneﬁ ts of single interventions 
are because of the direct therapeutic eﬀ ect of ART 
averting morbidity and mortality, rather than the 
secondary eﬀ ects of fewer HIV transmissions 
(appendix p 51). Furthermore, with adjusted 
calibrations, if health-care seeking behaviour is greater 
and is not strongly related to symptoms, pretreatment 
interventions generate less impact as patients enter the 
health-care system earlier without any additional 
intervention (appendix p 49). By contrast, if care is only 
sought when a patient is symptomatic, the outreach 
intervention before ART initiation has twice the impact, 
as patients do not return to care faster when lost 
(appendix p 50).
Finally, sensitivity analysis varying the unit costs of 
diﬀ erent aspects of care showed that the absolute cost 
of interventions is most sensitive to the cost of ART, 
but the rank order of cost per DALY averted for 
interventions is preserved when unit costs are varied 
over reasonable (±50%) ranges (appendix pp 53–55).
We identiﬁ ed a combination of ﬁ ve interventions that 
maximise the health gained from a budget of $700 million 
(table 4). This budget was chosen because it is about 
equal to the cost of implementing immediate ART, but is 
less than the cost of implementing home-based 
counselling and testing in isolation. The ﬁ ve selected 
interventions, in the order in which they were added 
with increasing budget, were: pre-ART outreach, 
facilitated linkage, voluntary counselling and testing 
point-of-care CD4, point-of-care CD4, and on-ART 
outreach. The next intervention to be added would be 
enhanced counselling and testing, comprising a set of 
interventions that act on each part of the cascade at a total 
budget 67% lower than that of the home-based 
counselling and testing intervention in isolation (table 4).
Collectively, this combination of interventions reduces 
AIDS deaths by 19% relative to baseline, the same 
reduction as the universal test-and-treat intervention, 
and averts 69% as many DALYs. It averts 77% more 
DALYs 
averted 
(million)
Additional 
cost relative to 
baseline (2013; 
million US$)
ICER* ACER†
Facilitated linkage 0·10 $39·75 $383·97 $383·97
Facilitated linkage and on-ART outreach 0·81 $406·78 $518·30 $501·17
Facilitated linkage, on-ART outreach, and VCT 
point-of-care CD4
0·88 $457·03 $783·02 $521·82
Facilitated linkage, on-ART outreach, VCT point-of-care 
CD4, pre-ART outreach
1·09 $623·33 $774·53 $571·57
Facilitated linkage, on-ART outreach, VCT point-of-care 
CD4, pre-ART outreach, and point-of-care CD4
1·10 $630·99 $543·24 $571·21
Facilitated linkage, on-ART outreach, VCT point-of-care 
CD4, pre-ART outreach, point-of-care CD4, and 
immediate ART
1·68 $1123·06 $852·10 $667·64
Intervention results in table 3 cannot be combined additively to arrive at those listed above because these results are 
generated with a dynamic model. Interventions were considered cost-eﬀ ective if ACER was less than 50% of GDP per 
capita for Kenya in 2013 (US$1242).24 DALY=disability-adjusted life-year. ICER=incremental cost-eﬀ ectiveness ratio. 
ACER=average cost-eﬀ ectiveness ratio. ART=antiretroviral therapy. VCT=voluntary counselling and testing. *Cost per 
DALY averted compared with previous increment. †Cost per DALY averted compared with baseline.
Table 4: DALYs averted and additional cost of implementing a combination of interventions between 
2010 and 2030 
DALYS averted 
between 2010 
and 2030 
(million)
Additional cost 
between 2010 
and 2030 (2013; 
million US$)
Cost per DALY 
averted 
compared with 
baseline (ACER)*
AIDS deaths 
averted (%)
HBCT 0·96 $2241·11 $2324·76 11·56 
Enhanced counselling and testing 0·24 $253·76 $1062·06 2·94
HBCT (with point-of-care CD4) 1·61 $2600·75 $1616·71 19·12
Facilitated linkage 0·10 $39·75 $383·97 1·02
VCT point-of-care CD4 0·13 $63·93 $474·19 1·46
Pre-ART outreach 0·26 $217·74 $822·99 3·81
Improved care 0·16 $156·74 $1008·24 2·01
Point-of-care CD4 0·11 $107·40 $953·35 1·66 
On-ART outreach 0·71 $355·92 $499·41 13·85 
Adherence 0·46 $364·41 $787·45 5·56 
Immediate ART 0·62 $552·02 $895·12 8·32 
Universal test and treat 1·60 $2813·84 $1760·10 19·11 
DALY=disability-adjusted life-year. ACER=average cost-eﬀ ectiveness ratio. HBCT=home-based counselling and testing. 
VCT=voluntary counselling and testing. ART=antiretroviral therapy. *Calculations had an SE of US$150.
Table 3: DALYs averted and additional cost of care for individual interventions between 2010 and 2030 
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DALYs than the immediate ART intervention. However, 
the combination of cascade interventions costed 22% as 
much as universal test and treat and only 14% more than 
immediate ART. This combination approach is estimated 
to be cost-eﬀ ective, at a cost of $571 per DALY averted 
(46% GDP per capita; ﬁ gure 3).
The comparatively low cost and high impact of the 
combination cascade intervention with this budget is the 
result of a collection of interventions operating 
synergistically, whereas the universal test and treat and 
immediate ART interventions incur ineﬃ  ciencies 
because of the remaining weaknesses in the cascade. 
These synergies among interventions are exempliﬁ ed by 
the point-of-care CD4 and pre-ART outreach interventions, 
for which the incremental cost-eﬀ ectiveness ratio of both 
interventions together is lower than for either intervention 
alone (table 4). A combination of both strengthening of 
the cascade and changing eligibility to immediate ART 
averted 31% of AIDS-related deaths relative to baseline, at 
a cost of 54% GDP per capita (table 4).
Discussion
Our results suggest that ART programmes can be 
substantially and cost-eﬀ ectively improved by 
strengthening each part of the care cascade through a 
combination of interventions. By contrast, simply moving 
to immediate ART would have less impact for the same 
cost as a combination of interventions. Although a 
universal test-and-treat strategy would generate greater 
health beneﬁ ts than a combination of interventions, it 
would not be cost-eﬀ ective if the weaknesses in the 
cascade were not resolved.
In the coming years, one of the most cost-eﬃ  cient 
interventions would be to ﬁ nd people who have 
disengaged from ART care (on-ART outreach). However, 
we reported that no individual pre-ART intervention has 
had a large eﬀ ect on patient outcomes except annual 
testing interventions with substantial costs (ﬁ gure 3). 
This ﬁ nding is a result of the multifaceted nature of 
weakness in the present pre-ART care cascade. We do 
ﬁ nd that combinations of interventions at all parts of the 
cascade can have a large eﬀ ect and be cost-eﬀ ective. The 
reason that interventions aﬀ ecting a single care stage 
have a modest eﬀ ect is because there are weaknesses 
throughout the care cascade, so any potential impact is 
attenuated by remaining weaknesses elsewhere.
Published trials have tended to examine the eﬀ ect 
of single interventions on the cascade,8 because 
measurements of the eﬀ ect of a combination of changes 
simultaneously poses challenges for robust experimental 
designs. Our model allows the eﬀ ect of interventions, 
applied individually or in combination, to be assessed 
across the entire cascade. However, implementation 
studies investigating the eﬀ ect and feasibility of complete 
combinations of interventions are needed to validate our 
ﬁ ndings. If greater synergy among interventions can be 
achieved than our model simulations, greater beneﬁ ts 
might be realised at lower costs. Alternatively, the 
increased complexity of operations could lead to higher 
costs and fewer beneﬁ ts. Therefore, trials of each 
individual and combination of interventions are needed 
to further conﬁ rm our results in western Kenya.
Attention has focused on the marginal therapeutic 
beneﬁ ts to a patient who has had early initiation of ART. 
A potentially large beneﬁ t of earlier ART initiation is to 
reduce the risk of losing a patient from the pretreatment 
monitoring phase, so lessening the chance of further 
transmission and the risk of death from AIDS before 
such a time as the patient might return to care. 
Furthermore, earlier initiation in the form of immediate 
ART would continue to prioritise treatment for patients 
with low CD4 counts as per WHO guidelines.11 
Our model did not consider the potential eﬀ ect of 
interventions that reposition ART initiation (eg, home 
initiation), which have been shown in recent trials.28
Neither of the strategies (combinations of cascade 
interventions or immediate ART for those presenting) 
would reduce the risk of deaths from AIDS among 
those not already diagnosed (appendix p 52). This issue 
would potentially exacerbate disparities in overall health 
between those who are better able to seek care. The 
eﬀ ect of immediate ART is enhanced by further 
strengthening of care through a combination of 
interventions (ﬁ gure 3). This result would lead to 
reductions in mortality before and after starting ART by 
outreach strategies returning more patients to treatment 
than in the absence of immediate ART. 
Our model suggests that a large proportion of 
HIV-related deaths occur in individuals never diagnosed 
and those who were diagnosed but never initiated 
treatment. These results are in agreement with data from 
general population cohort studies in Rakai (Uganda) and 
uMkhanyakude (South Africa).29 Many health data systems 
account only for individuals who have registered with the 
clinic, and therefore will not capture this source of AIDS 
mortality (ﬁ gure 2). Monitoring and evaluation frameworks 
for the cascade should therefore seek to quantify the extent 
to which deaths from AIDS are among those undiagnosed 
and treatment guidelines should recognise testing as an 
integral part of treatment programmes.
Therefore, to achieve the vision of eliminating deaths 
from AIDS, substantial active outreach is required to 
identify all individuals infected with HIV before needing 
ART. This goal is likely to incur substantial costs, but the 
exact cost is unknown and in well documented existing 
care programmes, costs vary between studies.17 For 
instance, an independent modelling analysis of a 
home-based counselling and testing intervention with 
active follow-up of patients piloted in Kwazulu-Natal 
(South Africa) reported that the intervention was cost 
eﬀ ective,9 whereas home-based counselling and testing 
with passive referral was not cost-eﬀ ective in our analysis. 
This discrepancy is likely because the KwaZulu-Natal 
study with active follow-up achieved a much higher rate 
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of linkage to care (90%) than the 30% we assumed for 
our simulated home-based counselling and testing 
intervention with passive referral. Ongoing analysis of 
AMPATH home-based counselling and testing rounds 
will provide an opportunity to examine both eﬃ  cacy and 
cost-eﬀ ectiveness of this intervention with active referral 
in a diﬀ erent setting, which might show important ways 
in which its eﬃ  cacy can be maximised.
Comparison of our alternative model parameterisations 
(appendix pp 49, 50) shows how patterns of health-care 
seeking behaviour can modify the eﬀ ect of interventions 
on population health, which has not been readily apparent 
from empirical observation.30 Health-care seeking 
behaviours have an important eﬀ ect on the value of 
outreach interventions. Such behaviours are hard to 
measure empirically. Additionally, intrinsic care seeking 
behaviour and the functionality of provider-initiated 
counselling and testing are hard to distinguish from each 
other in many contexts. For these reasons, extrapolation 
of the ﬁ ndings of diﬀ erent studies from diﬀ erent 
populations into a common framework, as we had to do 
in this model, is hard. As a result, although each 
assumption about the interventions is based on a real 
study, our ﬁ ndings can only be directionally informative. 
Furthermore, uncertainty increases over the 20 year 
simulation period, particularly as major changes to health 
care and treatment are diﬃ  cult to predict. For example, if 
a functional cure for HIV were developed or other 
important changes to treatment made, our results could 
become obsolete. Although the results presented rely 
largely on HIV health-care data from western Kenya 
served by AMPATH, we believe that our results will have 
the same broad relevance to other settings with large 
generalised epidemics in rural areas with an established 
ART programme.
Findings from other modelling studies that have relied 
on aggregated routine data to provide insight into care 
are in broad agreement with our results. For example, a 
similar modelling study focusing on South Africa has 
shown the potential impact and cost-eﬀ ectiveness of a 
combination of interventions strengthening the 
cascade.31 Additionally, other modelling studies have 
described the cost-eﬀ ectiveness of immediate ART 
(Rwanda)32 and treatment re-initiation interventions 
(South Africa).33 These diﬀ erences in intervention 
cost-eﬀ ectiveness emphasise variations in the state of 
care by location and the risk of directly comparing model 
outputs resulting from potential inconsistencies in 
approaches and assumptions.
Aspirations for HIV care and treatment have increased 
rapidly in recent years. The UNAIDS 90-90-90 strategy 
set out three ambitious targets to be achieved by 2020: 
90% of people with HIV diagnosed, 90% of those on 
treatment, and 90% of them virally suppressed.13 Some 
countries are already moving ahead to universal eligibility 
for ART;1,34 new data are emerging on clinical beneﬁ ts of 
ART,35 many studies on cascade interventions are being 
reported,8 and WHO has recently released new guidance 
for ART programmes encouraging immediate initiation 
of treatment for all individuals positive for HIV.11 
As countries move towards these targets and consider 
moves to new guidelines, integrating all available care 
cascade data with the perspective of improving health for 
the population is going to be especially important. 
Our results suggest that there is substantial scope for 
programmes to improve population health and that 
alternative sets of strategies are available that will be 
consistent with their particular aims and budget.
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